1. Home
  2. Live Updates
  3. Ruxolitinib jakafi

Live Breaking News & Updates on Ruxolitinib jakafi

Stay informed with the latest breaking news from Ruxolitinib jakafi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ruxolitinib jakafi and stay connected to the pulse of your community

Dr Gangat on the Evolution of JAK Inhibitors in Myelofibrosis

Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.

Ruxolitinib-jakafi , Naseema-gangat , Department-of-medicine , Division-of-hematology , Mayo-clinic-rochester , Myelofibrosis , Jak-inhibitors ,

Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting

Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.


Gabriela-hobbs , Ruxolitinib-jakafi , News-network , News , Ruxolitinib , Myelofibrosis , Myeloproliferative-neoplasms- , D , Splenomegaly- ,

Dr Kuykendall on the FDA Approval of Momelotinib in Myelofibrosis

Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.

Ruxolitinib-jakafi , Andrew-kuykendall , Moffitt-cancer-center , Department-of-malignant-hematology , Malignant-hematology , D , Fda-approval-of-momelotinib-in-patients-with-myelofibrosis ,

Colchicine vs Afib; Winter Spike in Cardiac Arrests; Cardiologist Stabbed at Home

Recent developments of interest in cardiovascular medicine

United-states , Australia , South-korea , American , Australian , Korea , Nicole-lou , Ruxolitinib-jakafi , Association-of-cardiovascular-nursing , Journal-of-the-american-college-cardiology , American-heart-association , European-society-of-cardiology

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Ruxolitinib was found to improve spleen volume and tumor symptom score in patients with myelofibrosis, irrespective of their anemia and transfusion status, according to data from a post-hoc analysis of the phase 3 COMFORT-I and -II trials.

Germany , Ruxolitinib-jakafi , European-hematology-association-congress , Myelofibrosis-symptom-assessment-form , Hematology-association-congress , Kiladjianj-j ,

Dr Mascarenhas on First-line Treatment Decisions in Myelofibrosis

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.


John-mascarenhas , Ruxolitinib-jakafi , Icahn-school-of-medicine , Tisch-cancer-institute , Icahn-school , Mount-sinai , Blood-cancers , Myeloid-disorders , The-tisch-cancer-institute-at-mount-sinai , Onclive-tv , Myeloproliferative-neoplasms , Myelofibrosis

Polycythemia Vera Management Often Does Not Follow Guidelines

Clinicians treating patients with polycythemia vera are too reliant upon phlebotomy, data suggest.

Ruxolitinib-jakafi , Polycythemia-vera , Thrombotic-events , Phlebotomy , Hct-levels ,

FDA Issues Complete Response Letter for Ruxolitinib Extended-Release Tablets in MPNs

The FDA has issued a complete response letter for ruxolitinib extended-release tablets for use once daily in the treatment of patients with certain types of myelofibrosis, polycythemia vera, and graft-vs-host disease.



Ruxolitinib-jakafi , Accessed-march , Complete-response-letter- , Ruxolitinib-extended-release-tablets , Myelofibrosis , Polycythemia-vera , Graft-vs-host-disease- ,

Cellenkos Announces First Patient Dosed with CK0804 Cell Therapy in LIMBER-TREG108 Clinical Trial | DNA RNA and Cells

Cellenkos Announces First Patient Dosed with CK0804 Cell Therapy in LIMBER-TREG108 Clinical Trial

California , United-states , Houston , Texas , University-of-texas , Ekaterine-asatiani , Lucia-masarova , Tara-sadeghi , Ruxolitinib-jakafi , Cellenkos-inc , University-of-california , University-of-texas-md-anderson-cancer-center

Cellenkos Announces First Patient Dosed with CK0804 Cell Therapy in LIMBER-TREG108 Clinical Trial

/PRNewswire/ -- Cellenkos Inc, a clinical stage biotechnology company focused on the development of allogeneic, off-the-shelf, T regulatory cell therapies...

California , United-states , Houston , Texas , University-of-texas , Ekaterine-asatiani , Lucia-masarova , Tara-sadeghi , Ruxolitinib-jakafi , Prnewswire-cellenkos-inc , Cellenkos-inc , University-of-california